Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.
Cleo A. Samuel-Ryals, PhD
Advertisement
Articles by Cleo A. Samuel-Ryals, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
2
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
3
Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment
4
CKD Stage, Proteinuria Tied to Higher HCRU in IgAN
5